###### Strengths and limitations of this study

-   This study will be a multicentre, randomised clinical trial to compare two therapeutic strategies based on early brain monitoring in patients with severe traumatic brain injury (TBI): intracranial pressure (ICP) alone versus ICP plus brain tissue oxygenation pressure (PbtO~2~).

-   This study is an open-label, non-blinded trial due to the nature of the intervention (PbtO~2~ monitoring). However, outcome assessors and statisticians will be blinded to patient allocation.

-   This study will collect extensive data during the first 5 days on admission. The maximum predefined delay of 16 hours post-TBI to allow inclusion represents a compromise that allows transportation to the participating site, patient screening and randomisation.

Introduction {#s1}
============

Despite substantial efforts made over the past decades, the mortality rate following severe traumatic brain injury (TBI), as defined by an initial Glasgow Coma Scale (GCS) score of less than 9, remains within the range of 30% and 50%, and only 20% of such patients will avoid lasting disabilities.[@R1] TBI initiates a cascade of events that can lead to secondary brain damage or exacerbate the primary injury, and which develops hours to days after the initial insult. The concern over secondary brain damage is the focus of modern TBI management. The thresholds for irreversible tissue damage following TBI indicate a particular vulnerability of injured brain.[@R2]

The early recognition of secondary brain damage relies on neuromonitoring in critically ill sedated patients. International guidelines emphasise the use of intracranial pressure (ICP) monitoring following severe TBI, and the continuous calculation of cerebral perfusion pressure (CPP, with CPP=mean arterial pressure -- ICP). To prevent brain ischaemia due to elevated ICP, maintenance of CPP between 60 and 70 mm Hg and ICP below 20 mm Hg is recommended.[@R3] Indeed intracranial hypertension, as defined by ICP values over 20 mm Hg, is considered as an independent risk factor of mortality and neurological disabilities. However, clinical studies have demonstrated that episodes of brain ischaemia/hypoxia are common despite optimisation of CPP or normalisation of ICP, and are independently associated with poorer patient outcome.[@R5] Brain tissue hypoxia resulting from the imbalance between oxygen supply to the brain tissue and its utilisation is considered a major cause of the development of secondary brain damage, and thereby poor neurological outcome.[@R6]

Monitoring brain tissue oxygenation after TBI may help clinicians to initiate adequate reparative actions when episodes of brain ischaemia/hypoxia are identified. Measuring cerebral tissue oxygen tension can be safely and reliably achieved at the bedside using brain tissue oxygen pressure (PbtO~2~) probes surgically inserted into the brain parenchyma.[@R7] PbtO~2~ measurements reflect the diffusion of dissolved plasma oxygen across the blood--brain barrier.[@R8] PbtO~2~ values lower than 15 mm Hg for more than 30 min were shown to be an independent predictor of unfavourable outcome and death.[@R9] The aggressive treatment of low PbtO~2~ values has been associated with better outcome compared with standard ICP/CPP-directed therapy in cohort studies of severely head-injured patients.[@R11] However, others were unable to find similar benefits on patient outcome.[@R14] All these studies were, however, uncontrolled, single-centre, and mostly retrospective. A randomised controlled trial recently showed that the information given by PbtO~2~ could help reduce the negative impact of brain tissue hypoxia with a trend towards more favourable outcome of patients in the PbtO~2~ treatment-guided group.[@R18]

The present programme will assess the impact of an early ICP and PbtO~2~ monitoring-based therapeutic strategy on neurological outcome in a randomised controlled trial. Each patient included in this study will enter into a 5-day intensive treatment modality to maintain ICP alone or ICP and PbtO~2~ within predefined values. The recent expert conference on algorithms for the management of patients with TBI with PbtO~2~ and ICP monitoring[@R19] prompted us to publish the design of our ongoing randomised controlled trial OxyTC. An ancillary study will investigate the volume of brain lesions defined by abnormal values of mean diffusivity using magnetic resonance diffusion tension imaging (DTI) in the two groups of patients.

The primary objective of the study is to determine whether early optimisation of brain oxygenation during the first 5 days after severe non-penetrating TBI improves neurological outcome at 6 months. Secondary objectives are to determine whether early optimisation of brain oxygenation improves survival at day 28, quality of life at 6 and 12 months, and neurological outcome at 12 months after TBI, and affects therapeutic intensity and incidence of critical events during the first 5 days of the intensive care unit (ICU) stay. The ancillary objective is to determine whether the volume of brain lesions after injury as measured with multiparametric, quantitative MRI on average is reduced with a therapeutic strategy based on PbtO~2~ and ICP measurements.

Methods and analysis {#s2}
====================

Trial design {#s2-1}
------------

The OxyTC trial is a national, multicentre, open-labelled, randomised controlled superiority trial with two parallel groups and 1:1 allocation ratio. [Figure 1](#F1){ref-type="fig"} shows the study design and flow of the OxyTC trial.

![Study design and flow of the Oxy-TC trial. ICP, intracranial pressure; ICU, intensive care unit; PbtO~2~, brain tissue oxygen pressure.](bmjopen-2020-040550f01){#F1}

Study setting {#s2-2}
-------------

The OxyTC trial includes 22 tertiary referral centres within university hospitals (Grenoble, Saint-Etienne, Rennes, Clermont-Ferrand, La Reunion, Bordeaux, Nancy, Marseille, Besançon, Lille, Nice, Paris Pitié-Salpêtrière, Poitiers, Rouen, Strasbourg, Dijon, Caen, Toulouse, Nimes, Angers) and non-university hospitals (Annecy, Toulon). Each centre was chosen on documentation for patient availability and experience in care management of patients with severe TBI.

Study population {#s2-3}
----------------

Patients are included if they meet the following criteria: aged between 18 and 75 years, admitted for a severe non-penetrating TBI with GCS score 3--8 and motor component 1--5, require ICP monitoring and continuous sedation/analgesia for more than 48 hours, and are mechanically ventilated with stable condition. Intracerebral monitoring (ICP with or without PbtO~2~) must be in place within the first 16 hours from injury. Patients may have extracranial lesions but not quadriplegia. French-speaking or English-speaking patients must be affiliated to either the French social security system or other social security system of another european member state, and give their written informed consent through legal surrogates or relatives.

Patients are excluded if they have one of the following criteria: penetrating head injury, GCS score 3 with bilateral fixed dilated pupils, decompressive craniectomy and no repositioning of the bone flap after subdural hematoma evacuation surgery prior to enrolment, contraindication to ICP and/or PbtO~2~ monitoring, persistent haemodynamic or respiratory instability despite treatments, body temperature \<34°C at randomisation, life expectancy \<24 hours, cardiac arrest at the initial presentation, associated quadriplegia, neuropsychiatric comorbidities that could interfere with the assessment of outcomes at 6 and 12 months, consent refusal, participation in another therapeutic study with written consent, impossibility to follow-up, ischaemic stroke after carotid arterial dissection, incapacitated patients in accordance with article L 1121--5 to L1121-8 of the French public health code: pregnant or breastfeeding women, persons deprived of liberty for civil reasons and those deprived of liberty on criminal charges, persons under psychiatric treatments and persons residing in a public health or social institution, adults under guardianship or adults permanently unable to express their wishes.

Enrolled patients are withdrawn for any of the following reasons: inability to measure ICP and/or PbtO~2~ during at least 48 hours, due to failure to insert catheter(s), permanent contraindication to intracerebral monitoring, defective or unavailable material, withdrawal of consent or consent to continue not granted, any serious adverse event or protocol deviation obliging, according to the in-charge physician, their exclusion, ischaemic stroke after traumatic carotid or vertebrobasilar artery dissection on CT scan at day 2.

Randomisation and blinding {#s2-4}
--------------------------

Patients with informed consent for participation who fulfil the inclusion criteria are randomised. Randomisation is performed by the site investigator or by the research coordinator through a dedicated password protected, SSL-encrypted website (Medsharing, Fontenay-sous-Bois, France) to allow concealed computer-generated random allocation. Protocol allocation is stratified by participating site and age (\<50 years and ≥50 years), and patients are assigned to ICP management (ICP group) or ICP and PbtO~2~ management (ICP + PbtO~2~ group) in a 1:1 ratio.

This trial is an open-label, non-blinded trial for the patient and the in-charge physician due to the nature of the intervention (presence or not of PbtO~2~ monitoring). Blinded assessment of the primary outcome will be performed at the coordinating centre and ensured by the entering of no identifying data or allocated group into the database. Statistical analyses will be based on blinded data.

Intervention {#s2-5}
------------

Patients eligible for inclusion are randomly assigned to the ICP group or to the ICP + PbtO~2~ group. The two groups of patients are similarly managed according to first-line treatments aimed at preventing any source of secondary brain damage (level 1): continuous sedation and analgesia, mechanical ventilation in normocapnia and normoxia, CPP 60--70 mm Hg, euvolaemia, normal levels of serum glucose and sodium, no anaemia and body temperature 36°C--38°C.[@R4] Patients are placed in the supine position with 15° head-up tilt.

The ICP group is treated according to international guidelines. If ICP\>20 mm Hg, treatments are gradually introduced (level 2 and level 3 if needed): deep level of sedation/analgesia, vasopressors, moderate hyperventilation, osmotic agents, external ventricular drainage, muscle relaxants, therapeutic hypothermia, decompressive craniectomy and barbiturates. The ICP + PbtO~2~ group is treated as above for the ICP group but also to maintain PbtO~2~ values over 20 mm Hg.[@R10] The optimisation of PbtO~2~ is thus in addition to that of ICP, and includes procedures directed at increasing blood oxygen supply to the brain: CPP increase, cardiac output optimisation, PaO~2~ increase, normocapnia and blood transfusion. The treatment algorithms according to allocated therapeutic strategy are shown in [figures 2 and 3](#F2 F3){ref-type="fig"}.

![Algorithms for the therapeutic strategies for the ICP group. CPP, cerebral perfusion pressure; ICP, intracranial pressure.](bmjopen-2020-040550f02){#F2}

![Algorithms for the therapeutic strategies for the ICP + PbtO~2~ group. CI, cardiac index; CPP, cerebral perfusion pressure; Hb, haemoglobin; ICP, intracranial pressure; PbtO2, brain tissue oxygen pressure.](bmjopen-2020-040550f03){#F3}

The maximal therapeutic intensity after severe TBI is usually observed during the first week of the ICU stay.[@R21] Given an expected stay of 10--20 days in the ICU after severe TBI and the necessity to reach the highest adherence to the study protocol, data are collected during the first 5 days following TBI and the initiation of one of two therapeutic algorithms. Beyond this, patients are treated according to guidelines[@R3] in each participating centre, and the use of PbtO~2~ and ICP monitoring is left at the discretion of the in-charge physician.

Study outcomes {#s2-6}
--------------

The primary outcome measure is the neurological status at 6 months after TBI as assessed using the extended Glasgow Outcome Scale (GOSE).[@R22] Treatment success is defined as the proportion of patients with unfavourable outcome, that is, GOSE score of 1 (death) to 4 (upper severe disability), is reduced by 30% in the ICP + PbtO~2~ group compared with the ICP group. Questionnaire scoring is conducted during a telephone interview by trained central outcome assessors who are blinded to the treatment arm.

Secondary outcomes are neurological outcome according to the GOSE at 12 months post-trauma and the Disability Rating Scale (DRS) at 6 and 12 months post-trauma, quality-of-life assessment: Functional Independence Measure and Medical Outcomes Study Short-Form 12 at 6 and 12 months post-trauma, mortality rate at day 28, therapeutic intensity during the first 5 days of the ICU stay as reflected by the number of level 2 and level 3 treatments to treat elevated ICP, and incidence of critical events during the first 5 days of the ICU stay as defined by ICP\>30 mm Hg lasting for 30 min or more, ICP\>40 mm Hg lasting for 5 min or more, PbtO~2~ \<10 mm Hg lasting for 30 min or more (ICP+PbtO~2~ group). For the ancillary study (MRI), the volume of cerebral lesions with abnormal mean diffusivity values is determined using diffusion tensor MR imaging between days 6 and 10 after severe TBI.

Data collection, data monitoring and adverse events {#s2-7}
---------------------------------------------------

At each participating site, data are collected and entered into the web-based electronic case report form (eCRF) (Medsharing, Fontenay-sous-Bois, France) by trial or clinical monitors (clinical research associates) under the supervision of the site principal investigators. The trial database will be created from the eCRF. Trained research coordinators monitor data collection. The study collects demographic, baseline information at randomisation, intracerebral monitoring measured hourly on day 1 to day 5, extracerebral information on vital signs and therapies measured every 6 hours on day 1 to day 5, biological data measured every 12 hours on day 1 to day 5, adverse events during the ICU stay and functional outcome at 6 and 12 months.

Several procedures to ensure data quality and protocol standardisation are in place to help minimise bias. They include: (1) a full-day investigator meeting for all principal investigators and lead research coordinators prior to study commencement to ensure consistency in procedures; (2) a site initiation visit conducted prior to site activation to provide protocol training for all site staff; (3) if needed, training sessions in PbtO~2~ management prior to site activation; (4) a detailed Oxy-TC operations manual provided for the investigators and research coordinators; (5) one or more visit as required from the project manager to each investigating site during the recruitment period to verify data sources and provide retraining as necessary; (6) centralised maintenance of the electronic database at Grenoble Clinical Research Centre and (7) for the MRI substudy, a validation of all participating sites including a quality check of MRI data, patient transport and MRI transfer procedures prior to site activation.

An independent data and safety monitoring committee (DSMC), comprising five experts in clinical trials, pharmacology, neurosurgery and intensive care medicine, was established before the first patients were enrolled. The DSMC advise the trial management committee as to whether the study should continue based on findings from the monitoring process and serious adverse events reported. The DSMC meet on the enrolment of every 50 randomised patients and on sponsor demand in case of suspected unexpected serious adverse events to PbtO~2~ probes or unexpected frequency of expected events. Meetings take place by videoconference or callconference.

It is recognised that the patient population with severe TBI will experience a number of common aberrations in laboratory values, as well as clinical signs and symptoms due to the severity of the underlying disease and the impact of standard therapies. These will not necessarily constitute an adverse event unless they require serious intervention or are considered a concern to the investigators based on their clinical judgement. Adverse events expected during this clinical trial are:

-   Related to severe TBI: death, severe neurological disability, organ failure during the ICU stay, hydrocephalus with dysfunction of external ventricular drainage and ICU-acquired complications, that is, ventilator-associated pneumonia, colonisation of central venous catheters, urinary tract infection, positive blood cultures, venous thromboembolism, gastroduodenal haemorrhage, neuromyopathy.

-   Related to insertion of intracerebral catheters: intracerebral haematoma, meningitis and cerebral thrombophlebitis, local infection, probe dysfunction.

Any adverse events classed as serious, that is, causing death, or requiring subsequent extension of ICU stay or intervention(s) not planned in the therapeutic algorithm, are reported to the sponsor (person responsible for the safety of the clinical trial).

Statistical considerations {#s2-8}
--------------------------

According to the available literature,[@R1] including the most recent data,[@R25] the rate of unfavourable neurological outcome (death and severe disability) following severe TBI is 55% (ICP group). Assuming a two-sided alpha risk of 0.05, the enrolment of two equally sized groups (148 patients per group) will have 80% power to detect a 30% reduction in relative risk of unfavourable neurological outcome at 6 months, that is, an absolute reduction of 17% in the rate of unfavourable neurological outcome. A total of 300 patients have to be recruited for the study. No interim analysis is planned.

The full statistical analysis plan will be developed prior to database freeze. Data will be expressed as mean and 95% CIs, or median and IQRs where appropriate. Comparisons will be conducted on an intention-to-treat basis. Missing data will be described and compared in terms of incidence between the two groups of patients. If the primary outcome is missing, data will be replaced as follows: no replacement if data are missing for less than 5% of patients, or using multiple imputation should data be missing from between 5% and 15% of patients. Patients not receiving the allocated protocol during the 5-day study, for example, early death or discharge from the ICU within the first 5 days, are followed up for their outcome and analysed on an intention-to-treat principle.

Baseline variables will be compared using X^2^ tests for equality of proportions, Student's t-test for normally distributed outcomes and Wilcoxon rank-sum tests otherwise. The primary outcome measure will be analysed using X^2^ tests. Data from the GOSE and DRS will be analysed using two-way analysis of variance for repeated measurements (M6/M12). Survival at day 28 will be tested with the Kaplan-Meier model and Cox model adjusted for age and centre. The results will be presented according to the Consolidated Standards of Reporting Trials guidelines for parallel group randomised trials.[@R26] Statistical significance will be declared when p≤0.05.

Study timescale {#s2-9}
---------------

2014--2016: protocol design and approval from the Institutional Review Board and from the National Agency for Medicines and Health Products Safety (ANSM, Agence Nationale de Sécurité du Médicament et des produits de santé), eCRF and randomisation system building, and quality control for the MRI ancillary study. Please see administrative information in [online supplementary file](#SP1){ref-type="supplementary-material"}.
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-   2016--2021: inclusion of patients. The first patient was recruited on 15 June 2016.

-   2022: 1-year follow-up of patients.

-   2023: cleaning and closure of the database, data analyses, manuscript writing and publication.

Patient and public involvement {#s2-10}
------------------------------

No patient involved

Ethics and dissemination {#s3}
========================

The protocol was approved by the Institutional Review Board of Sud-Est V on 3 December 2014 (14-CHUG-48) and by the National Agency for Medicines and Health Products Safety (ANSM) on 3 February 2015 (141 435B-31). Patients with severe TBI do not have the capacity to provide informed consent. Consent is, therefore, obtained through the signing of a consent form by a patient's relative or legal surrogate (person legally allowed to give consent on behalf of the patient) following a verbal presentation of the study provided by the site investigator, the reading through of the consent form, and answering of any questions.

In the event where the legal surrogate or patient's relative cannot attend the hospital to sign the consent form on time, or cannot be immediately determined or contacted, the patient may be enrolled with the signature of the site investigator, in accordance with French legislation (Procedural Authorisation). Consent from the legal surrogate or patient's relative is obtained later and as soon as possible. At such later stages, any patient whose recovery permits their decision making and communication is asked directly for their consent. A specific signed consent covering the main clinical trial and the ancillary MRI study must be obtained in the same conditions.

Results of this study will be presented at national and international meetings and published in peer-reviewed journals. Patients will not be individually notified regarding the results of the study. The principal publication from the study will be in the name of the Oxy-TC investigators with full credit assigned to all active, collaborating investigators, research coordinators and institutions.

Discussion {#s4}
==========

Compared with normal ICP, elevated ICP is known to be closely linked with higher mortality and disability rates.[@R27] Longer duration and greater intensity of episodes of high ICP were also associated with worse outcome in adults and children.[@R28] However, controlling ICP does not guarantee a good outcome, as shown with recent trials.[@R24] Instead, there is a growing interest in controlling brain oxygenation with the monitoring of brain hypoxia becoming part of the standard monitoring of TBI patients, that is, situations where oxygen supply to the brain and oxygen consumption are imbalanced such as arterial hypertension, low cardiac output, hypocapnia, systemic hypoxia, anaemia and hyperthermia. The diagnostic accuracy of near-infrared spectroscopy is limited in patients with TBI[@R31] and jugular venous oxygen saturation monitoring has been gradually replaced with PbtO~2~ in clinical practice.

The usefulness of PbtO~2~ monitoring in patients with TBI was recently demonstrated in a randomised trial (Brain Oxygen Optimization in Severe Traumatic brain injury, BOOST-2) where information provided by PbtO~2~ appeared to help reduce the proportion of time spent with brain hypoxia.[@R18] Although that study was not powered for clinical efficiency, a trend towards lower mortality and better outcome was observed in the ICP + PbtO~2~ group compared with the ICP group. These results prompted the authors to launch a phase III trial (BOOST-3; NCT03754114) that is open for recruitment since August 2019 using a similar methodological approach and primary outcome as the Oxy-TC trial. Both trials will provide evidence regarding the potential benefit or harm of invasive monitoring of brain oxygenation after severe TBI.

There are some limitations with the Oxy-TC protocol. First, no specific protocol directed at lowering ICP to ≤20 mm Hg is recommended. The choice of treatments is left to the discretion of the in-charge physician providing the reporting of the chosen therapies and results on ICP. In the cited expert consensus conference,[@R19] the ICP threshold at which treatment should be triggered was set at 22 mm Hg, a value not widely used in clinical practice. Second, patients with various brain lesions can be recruited provided they meet inclusion criteria. Some lesions might benefit from additional monitoring such as large contusions, while other lesions such as diffuse axonal injuries might not. However, the randomisation process should ensure the equal distribution of types of brain lesions across the two groups of patients. Third, patients aged over 75 years are excluded from this study. Indeed, the determination of TBI-related neurological outcome in the elderly can be affected by pre-existing cognitive alterations. We stratified the study population by age (\<50 years and ≥50 years) to prevent an uncontrolled effect of age. Fourth, the maximum predefined delay of 16 hours post-TBI to allow inclusion may be viewed as too long. While accounting for the necessity to initiate patient management at the early phase of TBI, this delay represents a compromise that allows transportation to the participating site, patient screening and randomisation. Fifth, quantitative MRI is an ancillary study. Initially, the quantification of brain lesion volume using DTI was the primary outcome of this study (see above). However, difficulties to access MRI during weekdays, some enrolled patients being unable to access MRI facilities between days 6 and 10 after TBI and/or technical problems relating to quality of MR imaging resulted in a large number of missing data. In agreement with the French legal authorities, the primary outcome was, therefore, changed on 7 February 2018 to compare the neurological outcome at 6 months between the two strategies. Sixth, we estimate that 300 patients will be needed to show a 30% relative reduction of unfavourable outcome in the ICP + PbtO~2~ group. This size effect is in line with other cohort studies.[@R11] In the BOOST-2 trial, a trend towards reduced mortality and better outcome in the ICP + PbtO~2~ group was observed with 53 patients in each group.

In conclusion, data obtained from this study may show that early monitoring of brain oxygenation using PbtO~2~ in addition to ICP monitoring can improve neurological outcome in patients with TBI. If this is the case, hundreds of patients per year could benefit from the combined monitoring. The resulting change of even just a few of these patients from an unfavourable to a favourable neurological outcome would also result in large savings for the healthcare system.

Supplementary Material
======================

###### Reviewer comments

###### Author\'s manuscript

**Contributors:** JFP conceived the study. GF, GA, EB, NJB, CDF, TG, LG, LP, BV and PB initiated the study design. JFP, MR, EB and PB helped with implementation. JFP and EB are grant holders. KS and JLB provided statistical expertise in clinical trial design, and JLB is conducting the primary statistical analysis.

**Funding:** This study is supported by a grant from the French National Program for Clinical Research (RCB 2014-A01674-43) and by an unrestricted grant from Integra Lifesciences (38RC14.039).

**Disclaimer:** These funding sources have no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results. Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France (Mrs M Sorrentino, Director General).

**Competing interests:** No.

**Patient consent for publication:** Not required.

**Provenance and peer review:** Not commissioned; externally peer reviewed.
